In aesthetic medicine, “energy-based treatment” is often discussed as though the device simply delivers heat into the skin. In reality, the clinical quality of an ultrasound treatment depends on far more than energy output alone. The relevant questions are anatomical: *Which tissue layer is being treated? At what depth? How consistently is energy deposited? Can the operator verify contact and tissue position while treating?* Ultherapy PRIME is designed around this anatomy-first approach, combining microfocused ultrasound with real-time ultrasound visualization (MFU-V) so that treatment can be planned and delivered with direct information about the patient’s tissue layers.
Real-time visualization is particularly important because facial anatomy is not uniform from one patient—or one facial region—to another. On ultrasound, the dermis, subcutaneous tissue, fibromuscular layers such as the SMAS/platysmal fascia, and bone have different echogenic characteristics. By identifying these structures before and during treatment, the clinician can better align the treatment depth with collagen-rich target tissue and confirm appropriate transducer coupling. This turns ultrasound imaging from a diagnostic-looking feature into a practical treatment-control mechanism.
Ultherapy PRIME provides treatment at nominal focal depths of 1.5 mm, 3.0 mm, and 4.5 mm. These depths are intended to address different anatomical levels, including the dermis, the dermal–subcutaneous interface and fibrous septal network, and deeper fibromuscular/fascial planes. The clinical value is not that one depth is universally “best,” but that multiple focal depths allow the physician to adapt treatment to tissue thickness and regional anatomy rather than applying a single-depth protocol to every face.
This is also why treatment depth should not be understood as a purely numerical setting. A 4.5-mm focal depth, for example, is meaningful only when the underlying anatomy supports that target. In thinner regions, or where tissue layers shift with facial contour, visualization helps the operator assess whether the intended focal zone corresponds to the desired tissue plane. The result is a more anatomically informed treatment strategy—especially in areas such as the jawline, submental region, and lower face, where soft-tissue thickness can vary substantially.
Once the correct tissue plane is selected, the next objective is controlled thermal coagulation. The source material describes Ultherapy PRIME as producing focal tissue temperatures in the approximate 60–70°C range, a range associated with collagen denaturation and initiation of a wound-healing response. Importantly, the treatment is not intended to heat the entire tissue volume uniformly. Instead, microfocused ultrasound creates discrete thermal coagulation points (TCPs) at depth while leaving intervening tissue relatively unaffected.
This controlled thermal injury initiates a biological remodeling sequence. Early inflammation and cytokine signaling are followed by macrophage activity, fibroblast proliferation, and extracellular-matrix synthesis. During remodeling, newly synthesized type III collagen is progressively replaced by more mature type I collagen, with ongoing collagen reorganization and elastin-related changes over subsequent weeks to months. From a clinical standpoint, this explains why MFU-V is not an “instant volumizing” treatment: its intended effect develops through tissue contraction and gradual matrix remodeling.
Precision is therefore not only about reaching a chosen depth; it also concerns the geometry and repeatability of the thermal lesions. The presentation shows comparative preclinical images in which MFU-V generates relatively uniform, well-focused TCPs, whereas several tested HIFU comparators demonstrate more variable or scattered coagulation patterns. Uniform lesion formation is relevant because consistent focal zones can support predictable energy deposition while preserving untreated tissue between individual TCPs.
These comparison images should be interpreted appropriately: they illustrate thermal lesion morphology under test conditions and are not, by themselves, proof of superior patient outcomes in a head-to-head clinical trial. Still, they reinforce an important medical principle for energy-based procedures—reproducibility of depth, focal volume, and spacing matters. A device that can consistently place small thermal zones in the intended plane gives the physician more control over the biological response being initiated.
The same logic is formalized in the See–Plan–Treat (SPT) treatment paradigm. “See” means using real-time DeepSEE imaging to evaluate tissue characteristics and identify collagen-rich layers. “Plan” means selecting the appropriate treatment subtype, focal depths, and line density for each region. “Treat” means delivering energy while maintaining proper coupling, pressure, and anatomical targeting. In practice, the three phases are interconnected: visualization continues to inform both planning and treatment rather than being used only once at the beginning.
This individualized workflow is clinically meaningful because facial aging is heterogeneous. Two patients with similar visible laxity may have different tissue thickness, fat distribution, skeletal support, and fibromuscular anatomy. Even within one patient, the optimal treatment approach can differ between the anterior cheek, jawline, submental area, and neck. SPT therefore frames personalization as an anatomical process, not simply a matter of changing the total number of treatment lines.
Clinical data in the presentation support the biological rationale, while also showing why evidence should be read with context. In a study by Kerscher and colleagues involving 22 women with moderate-to-severe jawline and submental sagging, a single MFU-V treatment was followed for 24 weeks. The presentation reports significant improvement in skin elasticity at weeks 12 and 24, with no adverse events recorded during follow-up and no meaningful disruption of epidermal barrier physiology. The delayed timing of the elasticity improvement is consistent with a remodeling-based mechanism rather than a purely immediate thermal effect.
A separate collagen-synthesis study by Sasaki and colleagues used a split-face design in two subjects undergoing rhytidectomy. Four weeks after MFU-V treatment, the presentation reports higher synthesis of both type I and type III collagen on the treated side, with overall collagen synthesis approximately 42% higher than the untreated side. These findings are mechanistically interesting, but the extremely small sample size means they should be viewed as supportive biological evidence rather than definitive clinical-effect estimates. Taken together, the studies presented in Section 2 support a coherent model: precise focal heating initiates collagen remodeling, and measurable changes in tissue function may continue to emerge for several months.
What ultimately distinguishes Ultherapy PRIME’s treatment concept is the integration of these elements into one workflow: visualize the anatomy, select the appropriate depth, create controlled focal thermal coagulation, and adapt treatment to the individual patient. For patients, this means that a non-surgical ultrasound lifting procedure can be approached with greater anatomical specificity. For physicians, it means treatment decisions can be guided not only by what is visible on the surface, but also by what is actually present beneath it.
As with any medical aesthetic procedure, outcomes vary according to baseline anatomy, degree of laxity, treatment design, operator technique, and individual healing response. Appropriate patient selection and consultation with a qualified medical professional remain essential. The value of MFU-V is therefore not a promise of identical results for every patient, but a more informed method of delivering ultrasound energy to the tissue layers intended for treatment.
Medical Information Notice — This column provides general medical information and does not recommend specific treatments. The appropriate treatment may vary depending on individual skin conditions and health status.
